5:29 PM
 | 
Apr 23, 2010
 |  BC Extra  |  Company News

CHMP updates Fabrazyme recommendations

The European Medicines Agency's CHMP updated its treatment recommendations for Fabrazyme agalsidase beta from Genzyme Corp. (NASDAQ:GENZ) after the company announced further supply shortages for the Fabry's disease drug. For...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >